Stroke is a leading cause of death worldwide. Traditional treatments have limitations, stem cell therapy has potential for regeneration after ischemic stroke. This study evaluated the safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell (UC-MSC) infusion via the intravenous (IV) and intrathecal (IT) routes for treating neurological sequelae after ischemic stroke.

Hypoplastic left heart syndrome (HLHS) requires a series of 3-staged palliative operations, in which the right ventricle (RV) assumes systemic circulation under increased pressure-overload conditions. These patients have a shortened lifespan, often due to RV dysfunction. Neonatal cardiac progenitor cells (nCPCs) improve RV performance in animal models of pressure overload-induced RV dysfunction, as is experienced by HLHS patients.

To report long-term safety and efficacy of mesenchymal stem cells (MSCs) in combination with and without IFN-γ in patients with rheumatoid arthritis (RA), using pooled data from two randomised clinical trials followed by long-term extension (LTE) study.

The current trial assessed for the first time radiographic and histological alterations, following alveolar ridge preservation (ARP), using autogenous demineralized dentin graft carried in 0.2% high molecular weight sodium hyaluronate (ADDG+HA; test group) versus autogenous demineralized dentin graft (ADDG, control group) alone.

To assess the effect of intracoronary infusion of mesenchymal stem cells on the development of post-myocardial infarction heart failure.

Adavosertib is a highly selective, small molecule Wee1 inhibitor that sensitizes tumor cells to cytotoxic agents.

COVID-19 has become a global pandemic, potentially leading to conditions like ARDS. The infection triggers severe inflammation and cytokine storms, damaging the lungs and other organs. MSCs and their derived exosomes are suggested as therapeutic options for reducing inflammation and modulating the immune response. This study evaluates the safety and efficacy of exosomes from umbilical MSCs in ARDS patients.

Stroke-related long-term disability is primarily due to impaired motor function. Rehabilitation efforts have traditionally focused on central strategies while ignoring the affected muscles. Regenerative medicine approaches have emerged as a promising option for treating various conditions, including muscular disorders. The present study aims to compare the effects of intramuscular injections of mesenchymal stromal cells (MSCs) and Platelet-rich plasma (PRP) on motor recovery in poststroke survivors.

Mitochondrial dysfunction and stem cell exhaustion contribute to age-related immune decline, yet clinical interventions targeting immune aging are lacking. Recently, we demonstrated that urolithin A (UA), a mitophagy inducer, expands T memory stem cells (TSCM) and naive T cells in mice. In this randomized, double-blind, placebo-controlled trial, 50 healthy middle-aged adults received oral UA (1,000 mg day-1) or placebo for 4 weeks; time points of analysis were baseline and day 28. Primary outcomes were phenotypical changes in peripheral CD3+ T cell subsets and immune metabolic remodeling. UA expanded peripheral naive-like, less terminally exhausted CD8+ cells (treatment difference 0.50 percentage points; 95% CI = 0.16 to 0.83; P = 0.0437) while also increasing CD8+ fatty acid oxidation capacity (treatment difference = 14.72 percentage points; 95% confidence interval (CI) = 6.46 to 22.99; P = 0.0061). Secondary outcomes included changes in plasma cytokine levels (IL-6, TNF, IL-1β, IL-10), immune populations assessed via flow cytometry, immune cell function, and mitochondrial content. Analysis revealed augmented mitochondrial biogenesis in CD8+ cells, increased peripheral CD56dimCD16bright NK cells, and nonclassical CD14loCD16hi monocytes in UA-treated participants, as well as improved activation-elicited TNF secretion in T cells and bacterial uptake by monocytes. Exploratory single-cell RNA sequencing demonstrated UA-driven transcriptional shifts across immune populations, modulating pathways linked to inflammation and metabolism. These findings indicate that short-term UA supplementation modulates human immune cell composition and function, supporting its potential to counteract age-related immune decline and inflammaging. ClinicalTrials.gov registration number: NCT05735886 .

No clinical trials have reported on the wrinkle-improving effects of cosmetics which activate stem cells in vitro.

Focused high-energy extracorporeal shock-wave therapy (ESWT) promotes bone healing through neo-angiogenesis, pooling of stem cells, and activation of osteocytes. This study investigated whether additional intraoperative ESWT improves or accelerates the healing rate of scaphoid reconstruction with non-vascularised bone grafts in cases of pseudarthrosis.This randomised, controlled study included 93 patients who underwent scaphoid reconstruction with a non-vascularised bone graft (radius cancellous bone, iliac crest cancellous bone, or iliac crest corticocancellous graft). The patients were divided into two groups: an intervention group that received intraoperative ESWT in addition to the reconstruction, and a control group that received sole reconstruction. Healing rates as well as the percentage of osseous bridging between the scaphoid and the bone graft were evaluated and compared clinically and radiologically at 12, 18, and 24 weeks postoperatively.After 24 weeks, 80% of the scaphoids (37 of 46) in the intervention group had healed, compared with 66% (31 of 47) in the control group. Healing rates in the proximal third of the scaphoid were 77% in the intervention group and 76% in the control group. In the middle third, healing rates were 82% and 57%, respectively. All pseudarthroses of the distal third healed. After 12 weeks, the percentage of osseous bridging of the scaphoid distal to the graft was significantly higher in the intervention group (87% versus 80%), but not proximal to the graft.A single intraoperative ESWT improves the healing rate of scaphoid reconstruction with a non-vascularised bone graft and accelerates bone healing during the first 12 postoperative weeks.

Allogeneic mesenchymal stromal cell (ASC) therapy is a potential treatment option in patients with ischemic heart failure (HF). We aimed to investigate the effect of allogeneic Cardiology Stem Cell Center Adipose tissue derived mesenchymal Stromal Cell product (CSCC_ASC) by joining data from the international SCIENCE and the Danish ASC trial.

Diabetic foot ulcers (DFUs), which have high rates of recurrence, amputation, and death, are a significant complication in the therapy of diabetes. Chronic inflammation, vascular dysfunction, and peripheral neuropathy are the results of their etiology, which includes dysregulated glucose homeostasis. These elements contribute to the poor clinical outcomes of DFUs and their complexity. Exosomes, which are natural nanovesicles that promote intercellular communication by transporting functional molecular cargos such as proteins, lipids, and nucleic acids, are being investigated as novel treatment approaches for diabetic foot ulcers (DFUs). These exosomes present a viable therapy option for DFU because they can alter cellular functions and promote wound healing.

The management of diabetic foot ulcers in patients with peripheral artery disease remains challenging. Human placenta-derived cells (PDA-002), a mesenchymal stromal cell-like population obtained from full-term placental tissue, possess angiogenic and tissue regenerative properties. Participants were stratified based on peripheral artery disease status. A total of 159 individuals were randomly assigned to receive intramuscular PDA-002 at one of three doses (3 × 106, 10 × 106 and 30 × 106 cells) or a placebo. This Phase 2 multi-center, randomised, double-blind, placebo-controlled trial evaluated adults with chronic diabetic foot ulcers with and without peripheral artery disease. The primary efficacy endpoint was the proportion of participants achieving complete wound closure of the index ulcer within 3 months, with sustained closure maintained for an additional 4 weeks. PDA-002 was well-tolerated, with no treatment-related serious adverse events. Intramuscular PDA-002 treatment achieved the highest efficacy at the 3 × 106 cell dose within the peripheral artery disease subgroup (38.5% vs. 22.6% for placebo), meeting a stringent 4-week durability endpoint that surpassed the U.S. Food and Drug Administration's recommended 2-week sustainability criterion. PDA-002 shows promise as a breakthrough treatment for diabetic foot ulcers and peripheral artery disease, demonstrating efficacy with two intramuscular doses and no re-treatment. Trial Registration: ClinicalTrials.gov identifier: NCT # 02264288.

To evaluate the efficacy of mesenchymal stem cells (MSCs) as an adjuvant therapy for cytomegalovirus (CMV) pneumonia after allogeneic hematopoietic stem cell transplantation (allo-HSCT) through a prospective study. From June 2016 to June 2022, 43 patients were diagnosed with CMV pneumonia after allo-HSCT and received antiviral therapy, of whom 24 received MSCs infusion. The primary endpoints of the study were the cure rate and the time to cure of CMV pneumonia, and the secondary endpoint was the overall survival after CMV pneumonia. The 2-year overall survival post-pneumonia in MSCs group was significantly better than that in non-MSCs group (74% vs. 50%, p = 0.034). Cure rate of pneumonia in MSCs group was higher than that in non-MSCs group without statistical significance (79% vs. 63%, p = 0.245). Time (days) to cure in MSCs group was shorter than that in non-MSCs group without statistical significance (39[14-142] vs. 54[6-157], p = 0.765). The high mortality rate of CMV pneumonia after allo-HSCT leads to a poor prognosis. The use of MSCs improves the overall survival of CMV pneumonia. The cure rate and time to cure of pneumonia were not improved statistically. At present, there is still a lack of prospective studies on MSCs in the treatment of pneumonia after HSCT, which needs to be supplemented in the future.

Circulating tumor cells (CTC) represent a high-risk biomarker in newly diagnosed multiple myeloma (NDMM); however, their prognostic value among transplant-eligible (TE) patients receiving daratumumab/bortezomib/lenalidomide/dexamethasone (D-VRd) remains unknown. In this study, we analyzed CTC in the phase 3 PERSEUS/EMN017 trial. TE-NDMM patients were randomized (1:1) to D-VRd with daratumumab/lenalidomide maintenance (D-VRd group) or bortezomib/lenalidomide/dexamethasone (VRd) with lenalidomide maintenance (VRd group), both with transplant. A subset of 451 of 709 patients from PERSEUS (D-VRd, 231/355; VRd, 220/354) had screening blood samples collected for CTC analysis by flow cytometry. CTC were detected in 370 patients (82%; median limit of detection, 0.0004%). CTC were prognostic of progression-free survival (PFS), independent of other factors, as a continuous (hazard ratio [HR], 1.36 [95% confidence interval (CI), 1.15-1.60]; P< .001) and categorical variable (≥0.175% CTC-high, optimal threshold). D-VRd improved PFS vs VRd in CTC-low patients (4-year rates: 88% vs 74%; HR, 0.42 [95% CI, 0.25-0.70]; P = .0013). Regardless of study treatment, minimal residual disease (MRD)-negativity rates were lower in CTC-high vs CTC-low patients (10-5: 52.2% vs 66.2%; 10-6: 34.8% vs 52.4%). D-VRd significantly increased MRD-negativity rates vs VRd among CTC-high (10-5: 69.4% vs 33.3%; 10-6: 47.2% vs 21.2%; both P< .05) and CTC-low patients (10-5: 74.4% vs 57.8%; 10-6: 65.6% vs 38.5%; both P< .001), with similar observations for sustained MRD-negativity. CTC levels are an independent prognostic factor in TE-NDMM treated with standard-of-care frontline quadruplet. D-VRd improved and sustained MRD-negativity rates in CTC-high and CTC-low, and improved PFS for CTC-low with a positive trend in CTC-high patients. This trial was registered at www.clinicaltrials.gov as #NCT03710603.

In boys, constitutional delay of growth and puberty (CDGP) has been associated with diverse negative psychosocial effects. Albeit alleviating distress is one of the main reasons for inducing pubertal development, the impact of puberty-promoting treatment on psychosocial wellbeing is under-researched. Our objective was to investigate the impact of puberty-promoting therapies on the behavioural patterns as defined by the temperament characteristics emotionality, activity, and sociability (EAS) in boys with CDGP.

Radiation-induced skin injury (RSI) is a common complication of radiation therapy, that severely reduces the quality of life of patients, and there is currently no gold standard for treatment. Placental mesenchymal stem cells (PMSCs) have emerged as a promising therapeutic approach due to their regenerative and anti-inflammatory properties, and biomaterials can serve as cell scaffolds to prolong cell survival time. This study is the first to evaluate the safety and efficacy of the a topical application of PMSCs-embedded alginate hydrogel (PMSCs gel) in cancer patients suffering from RSI.

Anterior cruciate ligament (ACL) reconstruction (ACLR) surgery remains the prevailing standard of care for complete ACL ruptures but is not without risk. The aim of this study was to compare non-surgical, autologous bone marrow concentrate (BMC) with platelet products compared to exercise therapy for partial and complete, non-retracted ACL tears without meniscus injuries.

Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function.